Donation After Circulatory Death Expands Heart Transplant Access. 12/02/25
Cardiology Today
Welcome to Cardiology Today – Recorded December 02, 2025. This episode summarizes 5 key cardiology studies on topics like Angiotensin-(1-7) and hemocompatibility-related adverse events. Key takeaway: Donation After Circulatory Death Expands Heart Transplant Access..
Article Links:
Article 1: Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 2: Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 3: Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 4: Donation after circulatory death transplantation alleviates waitlist time for hard-to-transplant cardiac recipients. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Article 5: Angiotensin-(1-7) preconditioning during 10°C static preservation improves early post-transplant graft function in a rat lung transplantation model. (The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation)
Full episode page: https://podcast.explainheart.com/podcast/donation-after-circulatory-death-expands-heart-transplant-access-12-02-25/
Featured Articles
Article 1: Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40846115
Summary: The study demonstrated that the echocardiographic myocardial work index effectively evaluated cardiac performance in donor hearts during ex situ heart perfusion. This method provides functional assessment of marginal cardiac grafts, which are increasingly relied upon due to organ shortages. The research confirmed that the myocardial work index accurately indicated cardiac function. This functional evaluation contributes to better selection and utilization of donor hearts for transplantation.
Article 2: Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40819750
Summary: This study reported 2-year outcomes for apixaban anticoagulation in patients with left ventricular assist devices. Apixaban was previously established as feasible at 6 months without excess hemocompatibility-related adverse events. The current research provided crucial longer-term data regarding apixaban’s safety and efficacy profile in preventing major adverse events in left ventricular assist device recipients. It informed the extended use of apixaban for anticoagulation in this patient population.
Article 3: Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40769332
Summary: Sotatercept, a recently approved agent, addresses the underlying pathophysiology of pulmonary arterial hypertension by favoring pro-apoptotic pathways within the pulmonary artery. This distinct remodeling mechanism differentiates it from traditional vasodilator therapies. Sotatercept is used as an adjunctive treatment to existing vasodilator therapy for pulmonary arterial hypertension. This therapeutic approach provides a new strategy for managing this incurable disease.
Article 4: Donation after circulatory death transplantation alleviates waitlist time for hard-to-transplant cardiac recipients.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40752550
Summary: Donation after circulatory death heart transplantation increased the cardiac transplant donor pool. This strategy significantly decreased waitlist times for hard-to-transplant cardiac recipients. The data showed that patients with challenging characteristics gained improved access to transplantation through this method. This approach effectively alleviates organ shortages and enhances transplant opportunities for a vulnerable patient population.
Article 5: Angiotensin-(1-7) preconditioning during 10°C static preservation improves early post-transplant graft function in a rat lung transplantation model.
Journal: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40749754
Summary: Angiotensin-(1-7) preconditioning during 10 degrees Celsius static preservation improved early post-transplant graft function in a rat lung transplantation model. The treatment effectively reduced ischemia-reperfusion injury in acid-injured donor lungs. This demonstrated that the protective axis of the renin-angiotensin system enhances lung transplant outcomes. The findings established a therapeutic approach to mitigate early graft failure in lung transplantation.
Transcript
Today’s date is December 02, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Myocardial Work Index as an Indicator of Cardiac Function in Ex Situ Heart Perfusion. The study demonstrated that the echocardiographic myocardial work index effectively evaluated cardiac performance in donor hearts during ex situ heart perfusion. This method provides functional assessment of marginal cardiac grafts, which are increasingly relied upon due to organ shortages. The research confirmed that the myocardial work index accurately indicated cardiac function. This functional evaluation contributes to better selection and utilization of donor hearts for transplantation.
Article number two. Two-year outcomes in the direct oral anticoagulant apixaban in left ventricular assist devices (DOAC LVAD) study. This study reported 2-year outcomes for apixaban anticoagulation in patients with left ventricular assist devices. Apixaban was previously established as feasible at 6 months without excess hemocompatibility-related adverse events. The current research provided crucial longer-term data regarding apixaban’s safety and efficacy profile in preventing major adverse events in left ventricular assist device recipients. It informed the extended use of apixaban for anticoagulation in this patient population.
Article number three. Hemodynamic effects of sotatercept administration in pulmonary hypertension- Insights from remote monitoring. Sotatercept, a recently approved agent, addresses the underlying pathophysiology of pulmonary arterial hypertension by favoring pro-apoptotic pathways within the pulmonary artery. This distinct remodeling mechanism differentiates it from traditional vasodilator therapies. Sotatercept is used as an adjunctive treatment to existing vasodilator therapy for pulmonary arterial hypertension. This therapeutic approach provides a new strategy for managing this incurable disease.
Article number four. Donation after circulatory death transplantation alleviates waitlist time for hard-to-transplant cardiac recipients. Donation after circulatory death heart transplantation increased the cardiac transplant donor pool. This strategy significantly decreased waitlist times for hard-to-transplant cardiac recipients. The data showed that patients with challenging characteristics gained improved access to transplantation through this method. This approach effectively alleviates organ shortages and enhances transplant opportunities for a vulnerable patient population.
Article number five. Angiotensin-(1-7) preconditioning during 10°C static preservation improves early post-transplant graft function in a rat lung transplantation model. Angiotensin-(1-7) preconditioning during 10 degrees Celsius static preservation improved early post-transplant graft function in a rat lung transplantation model. The treatment effectively reduced ischemia-reperfusion injury in acid-injured donor lungs. This demonstrated that the protective axis of the renin-angiotensin system enhances lung transplant outcomes. The findings established a therapeutic approach to mitigate early graft failure in lung transplantation.
Thank you for listening. Don’t forget to subscribe.
Keywords
Angiotensin-(1-7), hemocompatibility-related adverse events, lung transplantation, waitlist time, donor heart assessment, Sotatercept, vasodilator therapy, pro-apoptotic pathways, graft function, cardiac recipients, Apixaban, static preservation, ischemia-reperfusion injury, donor pool, pulmonary artery remodeling, Myocardial Work Index, ex situ heart perfusion, heart transplantation, cardiac function, Donation after circulatory death, pulmonary arterial hypertension, anticoagulation, left ventricular assist device, direct oral anticoagulant.
About
Concise summaries of cardiovascular research for professionals.
Subscribe • Share • Follow
The post Donation After Circulatory Death Expands Heart Transplant Access. 12/02/25 first appeared on Cardiology Today.